Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$23.69 USD
-0.40 (-1.64%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $23.68 -0.01 (-0.04%) 6:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VKTX 23.69 -0.40(-1.64%)
Will VKTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
Where Does VKTX Stock Stand After the Obesity Pill Setback?
Other News for VKTX
VKTX forms Stochastic Reached Oversold on September 15
VKTX's price falls by 3.61% on September 12, though its technical setup remains stable.
The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter
SA Asks: Which biotechs could be acquired by year's end?
Is VKTX building bearish momentum? 180 Bearish Setup shows up after declining 0.5%